Form 4: Pliant Therapeutics Executive Hans Hull Sells Shares to Cover Tax Obligations

Hans Hull, Chief Business Officer of Pliant Therapeutics, sold 9,900 shares of common stock to cover withholding tax liabilities related to vesting performance-vested stock units.

Summary

• On July 10, 2024, Hans Hull, the Chief Business Officer of Pliant Therapeutics, sold 9,900 shares of the company's common stock.
• The sale was executed at a price of $11.56 per share.
• The transaction was a non-discretionary sale by the plan to cover withholding tax liabilities associated with the vesting of previously granted performance-vested stock units.
• Following the transaction, Hull directly owns 227,494 shares of Pliant Therapeutics.
• Hull also indirectly owns shares through The Sloger Hull Family Trust (3,821 shares), a trust for his minor child Child A Trust (13,985 shares), and a trust for his minor child Child B Trust (13,985 shares).
• Hull disclaims beneficial ownership of the shares held in the trusts except to the extent of his pecuniary interest.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The filing simply reports a stock sale for tax purposes, which is a routine transaction. There's no indication of positive or negative implications for the company's performance.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders. This sale appears to be related to tax obligations, which is a common reason for such transactions.

Comparison to Industry Standards

• Executive stock sales to cover tax obligations are a common occurrence in publicly traded companies.
• Similar transactions are regularly seen at companies like Amgen, Gilead, and Biogen, where executives often sell shares acquired through equity compensation to meet tax liabilities.
• The sale of 9,900 shares is relatively small compared to the total holdings of the reporting person, suggesting it is primarily for tax purposes rather than a significant change in investment strategy.

Stakeholder Impact

• The sale of shares by an executive could have a minor negative impact on shareholder sentiment, but is unlikely to be significant given the reason for the sale.

Key Dates